All In Biotech

Drug Trial Radar · NCT03474107

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 608 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

608

Actual

Start

Jun 27, 2018

Primary completion

Jul 15, 2020

Study completion Nov 27, 2025

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
Collaborators
Seagen Inc.
First posted
Mar 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy. This study compared progression-free survival on study therapy (PFS1); the overall response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 of participants treated with EV to participants treated with chemotherapy. In addition, this study evaluated the duration of response (DOR) per RECIST V1.1 of EV and chemotherapy and assessed the safety and tolerability of EV, as well as, the quality of life (QOL) and Patient Reported Outcomes (PRO) parameters.

Conditions

  • Ureteral Cancer
  • Urothelial Cancer
  • Bladder Cancer

Interventions

  • Enfortumab VedotinDrug

    Intravenous infusion

  • DocetaxelDrug

    Intravenous infusion

  • VinflunineDrug

    Intravenous infusion

  • PaclitaxelDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)

Locations

158 sites in 19 countries. Site status is shown where the registry gives one.

  • UCI Chao Family Comprehensive Cancer Center

    Orange, California

  • University of California

    Sacramento, California

  • Innovative Clinical Research

    Whittier, California

  • University of Colorado

    Denver, Colorado

  • Smilow Cancer Hospital at Yale-New Haven

    New Haven, Connecticut

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Florida Hospital

    Orlando, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Norton Cancer Institute

    Louisville, Kentucky

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Long Island Jewish Medical Center

    Lake Success, New York

  • Sidney Kimmel Center for Prostate and Urologic Cancers

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • White Plains Hospital Center for Cancer Care - Oncology Site

    White Plains, New York

  • Toledo Clinic Cancer Center

    Toledo, Ohio

  • Providence Portland Med Center

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Lifespan Rhode Island Hospital

    Providence, Rhode Island

  • Saint Francis Hospital

    Greenville, South Carolina

  • HOPE Cancer Center of East Texas

    Tyler, Texas

  • Benaroya Research Institute at Virginia Mason

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Site AR54001

    Buenos Aires, Argentina

  • Site AU61006

    Adelaide, Australia

  • Site AU61001

    Miranda, Australia

  • Site AU61004

    St Leonards, Australia

  • Site AU61002

    Sydney, Australia

  • Site AT43005

    Linz, Austria

  • Site AT43001

    Salzburg, Austria

  • Site AT43004

    Vienna, Austria

  • Site BE32011

    Aalst, Belgium

  • Site BE32007

    Brussels, Belgium

  • Site BE32013

    Brussels, Belgium

  • Site BE32010

    Charleroi, Belgium

  • Site BE32001

    Ghent, Belgium

  • Site BE32008

    Ghent, Belgium

  • Site BE32005

    Hasselt, Belgium

Showing 40 of 158 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.